References
- Steinmetz H, Steinmetz H, germing U, sauer A, et al. Myelodysplastic syndromes (MDS) in regular care in germany – the oldest patients come to the fore. Leuk Lymphoma. 2018;59:1244–1247.
- Zeidan AM, Hendrick F, Friedmann E, et al. Deferasirox therapy is associated with reduced mortality risk in a medicare population with myelodysplastic syndromes. J Comp Eff Res. 2015;4:327–340.
- Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10:223–232.
- Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079–2088.
- Zeidan AM, Wang R, Gross CP, et al. Modest improvement in survival of patients with refractory anemia with excess blasts in the hypomethylating agents era in the united states. Leuk Lymphoma. 2016;58:982–985.
- Zeidan AM, Davidoff AJ, Long JB, et al. Comparative clinical effectiveness of azacitidine versus decitabine in older patients with myelodysplastic syndromes. Br J Haematol. 2016;175:829–840.
- Kantarjian H, Oki Y, Garcia-Manero G, et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood. 2007;109:52–57.
- Zeidan AM, Sekeres MA, Garcia-Manero G, et al. Comparison of risk stratification tools in predicting outcomes of patients with higher-risk myelodysplastic syndromes treated with azanucleosides. Leukemia. 2016;30:649–657.
- Gangat N, Patnaik MM, Begna K, et al. Primary myelodysplastic syndromes: the mayo clinic experience with 1000 patients. Mayo Clin Proc. 2015;90:1623–1638.
- Al-Kali AZ, Al-kali AZ,D, bartley AC, et al. Outcome of myelodysplastic syndromes over time in the US: a national cancer data base study from 2004-2013. Blood. 2016;128:3604.
- Itzykson R, Thepot S, Quesnel B, et al. Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine. Blood. 2011;117:403–411.
- Bernal T, Martinez-Camblor P, Sanchez-Garcia J, et al. Effectiveness of azacitidine in unselected high-risk myelodysplastic syndromes: Results from the spanish registry. Leukemia. 2015;29:1875–1881.
- Zeidan AM, Stahl M, Sekeres MA, et al. A call for action: Increasing enrollment of untreated patients with higher-risk myelodysplastic syndromes in first-line clinical trials. Cancer. 2017;123:3662–3672.
- Sekeres MA, Othus M, List AF, et al. Randomized phase II study of azacitidine alone or in combination with lenalidomide or with vorinostat in higher-risk myelodysplastic syndromes and chronic myelomonocytic leukemia: North American intergroup study SWOG S1117. J Clin Oncol. 2017;35:2745–2753.
- Zeidan AM, Linhares Y, Gore SD. Current therapy of myelodysplastic syndromes. Blood Rev. 2013;27:243–259.